Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in pediatric interstitial lung disease (START/STOP randomized trial)
2013-003714-40Phase 2Active
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hydroxychloroquine in interstitial lung disease (ILD) (4 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: START HCQ block primary endpoint. Started Jul 2014; status: active.
02
Drugs
hydroxychloroquine
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on 2013-003714-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003714-40.